BRAF and malignant colon neoplasm: Intriguingly, siRNA knockdown of CDC37 also reduced the basal levels of ERK activation, and inhibited its reactivation, albeit moderately, in mutant BRAF colon cancer cells after treatment with AUY922 (Figure 5B).